Trial Profile
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 24 Jan 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.
- 24 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 23 Mar 2023 Planned End Date changed from 1 Jan 2024 to 1 Dec 2024.